Skip to main content
SpringerLink
Log in

Pharmacological Properties of Presynaptic Dopamine Receptor Agonists

  • Conference paper
Dyskinesia

Part of the book series: Psychopharmacology Supplementum ((PSYCHOPHARM,volume 2))

Abstract

Selective presynaptic dopamine receptor agonists appear to offer promise as putative antipsychotic agents with a low risk of extrapyramidal side-effects, including tardive dyskinesia. However, no such agent with a reasonable degree of selectivity has yet reached the stage of clinical trial.

In the present paper the particular pharmacological profile of presynaptic dopamine receptor (autoreceptor) agonists is described, and underlying mechanisms are discussed. Special attention is paid to the compound 3-(3-hydroxyphenyl-N-n-propylpiperidine (3-PPP), especially its levotatory enantiomer. This agent shows affinity for both pre- and postsynaptic dopamine receptors. Its intrinsic activity in different locations varies between virtually zero and 100%, leading to a mixture of agonist and antagonist properties. It is suggested that this variability depends on the adaptive properties of the dopamine receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andén NE, Ålander T, Grabowska-Andén M, Liljenberg B, Lindgren S, Thornstrom U (1984) The pharmacology of pre- and postsynaptic dopamine receptors; differential effects of dopamine receptor agonists and antagonists. In: Usdin E, Carlsson A, Dahlstrom A, Engel J A (eds) Catecholamines, vol. B. Liss, New York, p 19

    Google Scholar 

  • Arnt J, Hyttel J (1984) Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxydopamine lesions and by chronic reserpine treatment in rats. Neural Transm 60

    Google Scholar 

  • Arnt J, Christensen AV, Hyttel J, Larsen JJ, Svendsen O (1982) Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur J Pharmacol 86: 185–198

    Article  PubMed  CAS  Google Scholar 

  • Arnt J, Bógesó KP, Christensen AV, Hyttel J, Larsen JJ, Svendsen O (1983) Dopamine receptor agonistic effects of 3-PPP enantiomers. Psychopharmacology 81: 199–207

    Article  PubMed  CAS  Google Scholar 

  • Carlsson A (1983) Are “on-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway? J Neural Transm [Suppl] 19: 153–161

    CAS  Google Scholar 

  • Clark D, Engberg G, Pileblad E, Svensson TH, Carlsson A, Freeman AS, Bunney BS (1984) The effect of novel dopaminergic agonists on the nigrostriatal dopamine system. Proceedings of the 14th CINP congress. Clin Neuropharmacol (to be published)

    Google Scholar 

  • Eriksson E, Modigh K, Carlsson A (1983) Dopamine receptors involved in prolactin secretion pharmacologically characterized by use of 3-PPP enantiomers. Eur J Pharmacol 96: 29–36

    Article  PubMed  CAS  Google Scholar 

  • Feenstra MGP, Rollema H, Mulder TBA, Westerink BHG, Horn AS (1983) In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN. Life Sci 32: 1313–1323

    Article  PubMed  CAS  Google Scholar 

  • George SR, Watanabe M, Seeman P (1983) The brain D2 receptor differs from the pituitary D2 receptor. Abstracts of the 13th annual meeting. Society for Neuroscience, Boston

    Google Scholar 

  • Haggstrom JE, Gunne LM, Carlsson A, Wikstrom H (1983) Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic- induced dyskinesias. J Neurol Transm 58: 135–142

    Google Scholar 

  • Hjorth S, Carlsson A, Wikstrom H, Lindberg P, Sanchez D, Hacksell U, Arvidsson LE, Svensson U, Nilsson JLG (1981) 3-PPP, a new centrally acting DA receptor agonist with selectivity for autoreceptors. Life Sci 28: 1225–1238

    Article  PubMed  CAS  Google Scholar 

  • Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, Lindberg P, Hacksell U, Arvidsson LE, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81: 89–99

    Article  PubMed  CAS  Google Scholar 

  • Kenakin TP (1982) Organ selectivity of drugs. Alternatives to receptor selectivity. TIPS April 1982: 153 - 156

    Google Scholar 

  • Koch SW, Koe BK, Bacopoulos NG (1983) Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites. Eur J Pharmacol 92: 279–283

    Article  PubMed  CAS  Google Scholar 

  • Langer SZ, Arbilla S, Kamal L, Cantrill R (1983) Peripheral and central dopamine receptors modulating the release of neurotransmitters. Acta Pharm Suec [Suppl] 1: 108–117

    Google Scholar 

  • Magnusson T, Carlsson A, Lindberg P, Sanchez D (1983) Evidence for activation of dopaminergic autoreceptors by (-)-3-PPP. Acta Pharm Suec [Suppl] 1: 16–18

    Google Scholar 

  • Markstein R, Lahaye D (1983) In vitro effect of the racemic mixture and the (—)enantiomer of N-n-propyl-3-(3-hydroxyphenyl) piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic autoreceptor. J Neural Transm 58: 43–53

    Article  PubMed  CAS  Google Scholar 

  • Martin GE, Haubrich DR, Williams M (1981) Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. Eur J Pharmacol 76: 15–23

    Article  PubMed  CAS  Google Scholar 

  • Mikuni M, Gudelsky GA, Simonovic M, Meltzer HY (1984) Interaction of (+)- and (-)-3-PPP with the dopamine receptor in the anterior pituitary gland. Life Sci 34: 239–246

    Article  PubMed  CAS  Google Scholar 

  • Oberlander C, Boissier JR (1983) Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (—) 3-PPP and modification after receptor deafferentation. J Pharmacol (Paris) 14: 401–404

    CAS  Google Scholar 

  • Palacios JM, Wiederhold KH (1984) Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics, (to be published)

    Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313

    PubMed  CAS  Google Scholar 

  • Starke K (1984) Functional in vitro comparison of striatal pre- and postsynaptic dopamine receptors. In: Usdin E, Carlsson A, Dahlstrom A, Engel J A (eds) Catecholamines, vol. B. Liss, New York, p 5

    Google Scholar 

  • Svensson L, Ahlenius S (1983) Suppression of exploratory locomotor activity in the rat by the local application of 3-PPP enantiomers into the nucleus accumbens. Eur J Pharmacol 88: 393–397

    Article  PubMed  CAS  Google Scholar 

  • Wachtel H, Dorow R (1983) Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 32: 421–432

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Göteborg, P.O. Box 33031, S-40033, Göteborg, Sweden

    A. Carlsson

Authors
  1. A. Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Research, Psychiatry and Neurology Services at the Veterans Administration Medical Center, USA

    Daniel E. Casey MD (Clinical Investigator, Associate Professor, Collaborative Scientist) (Clinical Investigator, Associate Professor, Collaborative Scientist)

  2. Departments of Psychiatry and Neurology at the Oregon Health Sciences University, 97207, Portland, OR, USA

    Daniel E. Casey MD (Clinical Investigator, Associate Professor, Collaborative Scientist) (Clinical Investigator, Associate Professor, Collaborative Scientist)

  3. Oregon Regional Primate Research Center, 97006, Beaverton, OR, USA

    Daniel E. Casey MD (Clinical Investigator, Associate Professor, Collaborative Scientist) (Clinical Investigator, Associate Professor, Collaborative Scientist)

  4. Intramural Research Program, National Institute of Neurological and Communicative Disorders and Stroke, Department of Health and Human Services, National Institute of Health, 20205, Bethesda, MD, USA

    Thomas N. Chase MD (Director) (Director)

  5. H. Lundbeck A/S, Ottiliavej 7-9, DK-2500, Copenhagen-Valby, Denmark

    Anne Vibeke Christensen MSc Pharm, DSc (Vice-President, Director of Research) (Vice-President, Director of Research)

  6. Department AEH, Sct. Hans Mental Hospital, DK-4000, Roskilde, Denmark

    Jes Gerlach MD

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Carlsson, A. (1985). Pharmacological Properties of Presynaptic Dopamine Receptor Agonists. In: Casey, D.E., Chase, T.N., Christensen, A.V., Gerlach, J. (eds) Dyskinesia. Psychopharmacology Supplementum, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70140-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70140-5_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-70142-9

  • Online ISBN: 978-3-642-70140-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation